Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „consistent“
Suchtreffer
Begriffe & Kennungen
Clopidogrel HCS · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel Krka d.d. (previously Zopya) · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel Krka · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel TAD · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel Teva (hydrogen sulphate) · 4.5 · 7 Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction
Eintrag öffnenClopidogrel Viatris (previously Clopidogrel Taw Pharma) · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel Zentiva (previously Clopidogrel Winthrop) · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover) · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenConstella · 4.8 · Description of selected adverse reactions Diarrhoea is the most common adverse reaction and is consistent with
Eintrag öffnenCopalia HCT · 4.8 · * See section 4.4 Photosensitivity ** Mostly consistent with cholestasis
Eintrag öffnenCopalia · 4.8 · * Mostly consistent with cholestasis
Eintrag öffnenDafiro HCT · 4.8 · * See section 4.4 Photosensitivity ** Mostly consistent with cholestasis
Eintrag öffnenDafiro · 4.8 · * Mostly consistent with cholestasis
Eintrag öffnenDegevma · 4.8 · Overall safety profile is consistent in all approved indications for Degevma.
Eintrag öffnenDupixent · 4.8 · 15 Asthma The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent wit
Eintrag öffnenDupixent · 4.8 · 76 The long-term safety profile of dupilumab in EXCURSION was consistent with the safety profile observed in t
Eintrag öffnenDupixent · 4.8 · 77 The safety profile of dupilumab in the 96 weeks long term safety study (TRAVERSE) was consistent with the s
Eintrag öffnenDupixent · 4.8 · CRSwNP The safety profile of dupilumab in adults with CRSwNP through week 52 was consistent with the safety pr
Eintrag öffnenDupixent · 4.8 · CRSwNP The safety profile of dupilumab in adults with CRSwNP through week 52 was consistent with the safety pr
Eintrag öffnenEmselex · 4.8 · Summary of the safety profile Consistent with the pharmacological profile, the most commonly reported adverse
Eintrag öffnen